CASP8 promoter polymorphism, mRNA expression and risk of prostate cancer among Chinese men

Journal of Biomedical Research

Volumn 25, Issue 2, 2011, Pages 128-134

  Fu, Guangbo ^a   Tang, Jialin ^a   Wang, Meilin ^a   Qin, Chao ^b   Yan, Fu ^a   Ding, Qi ^b   Yin, Changjun ^b   Wang, Xinru ^a   Zhang, Zhengdong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Caspase 8; Genetic variation; Promoter polymorphism; Prostate cancer

Indexed keywords

CASPASE 8; MESSENGER RNA;

AGED; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER TISSUE; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN TISSUE; INDEL MUTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79955137263     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(11)60016-X     Document Type: Article

References (29)

1. A Jemal, R Siegel, E Ward, Y Hao, J Xu, MJ Thun Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. HG Sim, CW Cheng Changing demography of prostate cancer in Asia. Eur J Cancer 2005, 41:834-845.
3. Matsuda T, Saika K Comparison of time trends in prostate cancer incidence (1973 1997) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV VIII. Jpn J Clin Oncol 2007, 37:556-557.
4. Parkin DM, Bray F, Ferlay J, Pisani P Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
5. Matsuda T, Saika K Comparison of time trends in prostate cancer incidence (1973-2002) in Asia, from cancer incidence in five continents, Vols IV-IX. Jpn J Clin Oncol 2009, 39:468-469.
6. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001, 10:345-353.
7. Chokkalingam AP, Stanczyk FZ, Reichardt JK, Hsing AW Molecular epidemiology of prostate cancer: hormone-related genetic loci. Front Biosci 2007, 12:3436-3460.
8. Ntais C, Polycarpou A, Tsatsoulis A Molecular epidemiology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 2003, 149:469-477.
9. Zimmermann KC, Bonzon C, Green DR The machinery of programmed cell death. Pharmacol Ther 2001, 92:57-70.
10. de Visser KE, A Eichten, LM Coussens Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
11. Siegel RM Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 2006, 6:308-317.
12. Ho PK Hawkins CJ. Mammalian initiator apoptotic caspases. Febs J 2005, 272:5436-5453.
13. Cox A, Dunning AM, M Garcia-Closas, S Balasubramanian, MW Reed, KA Pooley, et al. A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 2007, 39:352-358.
14. Vecchi GD, P Verderio, S Pizzamiglio, S Manoukian, M Barile, S Fortuzzi, et al. Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases. Breast Cancer Res Treat 2009, 113:607-608.
15. G MacPherson, CS Healey, MD Teare, SP Balasubramanian, MW Reed, PH Pharoah, et al. Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 2004, 96:1866-1869.
16. Enjuanes A., Benavente Y., Bosch F., Martin-Guerrero I., Colomer D., Perez-Alvarez S., et al. Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 2008, 68(24):10178-10186.
17. Son J.W., Kang H.K., Chae M.H., Choi J.E., Park J.M., Lee W.K., et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet 2006, 169(2):121-127.
18. Sun T., Gao Y., Tan W., Ma S., Shi Y., Yao J., et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007, 39(5):605-613.
19. Wang M., Zhang Z., Tian Y., Shao J., Zhang Z. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res 2009, 15(7):2567-2572.
20. Frank B., Hemminki K., Wappenschmidt B., Meindl A., Klaes R., Schmutzler R.K., et al. Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. Carcinogenesis 2006, 27(3):606-609.
21. Lubahn J., Berndt S.I., Jin C.H., Klim A., Luly J., Wu W.S., et al. Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. Prostate 2009, 70(6):646-653.
22. Haiman C.A., Garcia R.R., Kolonel L.N., Henderson B.E., Wu A.H., Le Marchand L. A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 2008, 40(3):259-260.
23. Wang M., Zhang Z., Zhu H., Fu G., Wang S., Wu D., et al. A novel functional polymorphism C1797G in the MDM2 promoter is associated with risk of bladder cancer in a Chinese population. Clin Cancer Res 2008, 14(11):3633-3640.
24. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407(6805):770-776.
25. Frank B., Rigas S.H., Bermejo J.L., Wiestler M., Wagner K., Hemminki K., et al. The CASP8 -652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 2008, 111(1):139-144.
26. Pittman A.M., Broderick P., Sullivan K., Fielding S., Webb E., Penegar S., et al. CASP8 variants D302H and -652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. Br J Cancer 2008, 98(8):1434-1436.
27. Park S., Bae J., Nam B.H., Yoo K.Y. Aetiology of cancer in Asia. Asian Pac J Cancer Prev 2008, 9(3):371-380.
28. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452(7187):638-642.
29. Bondy S.J., Rehm J., Ashley M.J., Walsh G., Single E., Room R. Low-risk drinking guidelines: the scientific evidence. Can J Public Health 1999, 90(4):264-270. PubMed.